Kazia Therapeutics deploys the best available scientific insights to address the world's most challenging cancers.

GDC-0084 inhibits the PI3K pathway that is thought to be critical to the development of certain kinds of tumours. 


Cantrixil (TRE-E-002-1) is a third-generation benzopyran that targets slower dividing 'tumour-initiating cells' thereby helping combat the problems of resistance and recurrence that occur with chemotherapy.